EHA 2025 | Findings from a Phase I trial of bexobrutideg, a BTK degrader, for the treatment of R/R CLL

We are really excited to present our updated data from our Phase I trial studying our Nurix degrader, the bexobrutideg. We just had the name coming out and the outcome in the relapsed refractory CLL setting. The data is very exciting. We are seeing a lot of, I mean, we had a total of 48 patients, of them 47 total patients were evaluable and we were able to see overall response rate of 80% with one CR. And this is actually like very promising and exciting for us in the CLL field because the population was mainly a very hard-to-treat population who already saw many treatments. The median line of therapy for this population was four lines with as high as 12 lines of therapy. So you can imagine how heavily pretreated this population was. And 80% of these patients actually did see BTK inhibitors, either covalent or non-covalent and BCL2 inhibitors. So we are already targeting an area of unmet need in the population. And the safety was also really good. All patients tolerated the treatment pretty well. We only have one therapy discontinuation out of the 47 due to adverse events, which is really amazing. Also showing that this is a very tolerable medication so we are very excited for these updates and we are happy hoping even for more and more evolving data for this small molecular drug.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.